Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaglenastat + RT + TMZ in IDH-Mutated Diffuse and Anaplastic Astrocytoma
NCT03528642Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2019
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of telaglenastat in astrocytoma, sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose and Recommended Phase 2 Dose at 6.5 weeks. Started May 2019; status: active, not recruiting.
02
Drugs
telaglenastat
03
Conditions
astrocytoma
Beyond the preview
Go deeper on NCT03528642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03528642.